Vortioxetine: a new antidepressant to treat depressive episodes

Vortioxetine is a new antidepressant, which mechanism of action is multimodal, targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin transporter (5-HTT). Its efficacy and safety were assessed in fourteen studies including more than 3700 patients with a major depressive episo...

Full description

Saved in:
Bibliographic Details
Published inEncéphale Vol. 42; no. 1; p. 48
Main Authors Colle, R, Corruble, E
Format Journal Article
LanguageFrench
Published France 01.02.2016
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Vortioxetine is a new antidepressant, which mechanism of action is multimodal, targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin transporter (5-HTT). Its efficacy and safety were assessed in fourteen studies including more than 3700 patients with a major depressive episode and treated with vortioxetine. In short-term studies (8 weeks), vortioxetine is more efficacious than placebo in decreasing depressive symptoms as measured by the MADRS total score, response rate (vortioxetine: 53.2% vs placebo: 35.2%) and remission rate (vortioxetine: 29.2% vs placebo: 19.3%). In a long-term study (52 weeks), vortioxetine is also superior to placebo in preventing relapses and recurrences. Moreover, in second line treatment, after failure of a first line selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrin reuptake inhibitor (SNRI), vortioxetine is superior to agomelatine in improving depressive symptoms and achieving response and remission. Furthermore, the positive effects of vortioxetine on improvement of cognitive symptoms of major depressive episodes are particularly well established in several clinical trials. The tolerability profile of vortioxetine is favourable. The recommended daily posology of vortioxetine is 10mg/d. Vortioxetine is a new antidepressant drug with a multimodal mechanism of action, well-documented efficacy and safety profiles.
AbstractList Vortioxetine is a new antidepressant, which mechanism of action is multimodal, targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin transporter (5-HTT). Its efficacy and safety were assessed in fourteen studies including more than 3700 patients with a major depressive episode and treated with vortioxetine. In short-term studies (8 weeks), vortioxetine is more efficacious than placebo in decreasing depressive symptoms as measured by the MADRS total score, response rate (vortioxetine: 53.2% vs placebo: 35.2%) and remission rate (vortioxetine: 29.2% vs placebo: 19.3%). In a long-term study (52 weeks), vortioxetine is also superior to placebo in preventing relapses and recurrences. Moreover, in second line treatment, after failure of a first line selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrin reuptake inhibitor (SNRI), vortioxetine is superior to agomelatine in improving depressive symptoms and achieving response and remission. Furthermore, the positive effects of vortioxetine on improvement of cognitive symptoms of major depressive episodes are particularly well established in several clinical trials. The tolerability profile of vortioxetine is favourable. The recommended daily posology of vortioxetine is 10mg/d. Vortioxetine is a new antidepressant drug with a multimodal mechanism of action, well-documented efficacy and safety profiles.
Author Corruble, E
Colle, R
Author_xml – sequence: 1
  givenname: R
  surname: Colle
  fullname: Colle, R
  organization: Faculté de médecine Paris Sud, Inserm U 1178 santé mentale et santé publique, équipe « Dépression et Antidépresseurs », CHU de Bicêtre, AP-HP, 94276 Le Kremlin-Bicêtre, France; Service de psychiatrie, CHU de Bicêtre, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre cedex, France
– sequence: 2
  givenname: E
  surname: Corruble
  fullname: Corruble, E
  email: emmanuelle.corruble@bct.aphp.fr
  organization: Faculté de médecine Paris Sud, Inserm U 1178 santé mentale et santé publique, équipe « Dépression et Antidépresseurs », CHU de Bicêtre, AP-HP, 94276 Le Kremlin-Bicêtre, France; Service de psychiatrie, CHU de Bicêtre, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre cedex, France. Electronic address: emmanuelle.corruble@bct.aphp.fr
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26358483$$D View this record in MEDLINE/PubMed
BookMark eNo1j8tKAzEYhbOo2Is-gSB5gYl_LpNk3IgUb1Bw07otmcw_kGIzYRJvb--AdXU-zuLwnSWZxSEiIVccGAeubw4Mo8fEBPCagWEAZkYWAFxWBkDPyTLnA4DgqoFzMhda1lZZuSB3b8NYwvCNJUS8pY5G_KIultBhGjHnCWkZaBnRFXrqwidSTCEPHeYLcta794yXp1yR3ePDdv1cbV6fXtb3mypxxUtVCzFpWC28UV60XqHUUvgetLdtYwz2jZET2GZy7GRrTO97a1BhbUBpJ1bk-m83fbRH7PZpDEc3_uz_n4hfmapMGQ
ContentType Journal Article
Copyright Copyright © 2015 L’Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.
Copyright_xml – notice: Copyright © 2015 L’Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1016/j.encep.2015.07.007
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
DocumentTitleAlternate La vortioxétine : un nouvel antidépresseur pour traiter les épisodes dépressifs caractérisés
ExternalDocumentID 26358483
Genre Journal Article
Review
GroupedDBID 08J
08T
0R~
457
53G
5RE
AAEDT
AAEDW
AALRI
AAXUO
ADBBV
AFJKZ
AFNOS
AFTJW
AITUG
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AOOFG
CGR
CUY
CVF
EBS
ECM
EIF
EJD
FDB
HZ~
NPM
O9-
RGL
RIG
ROL
SEM
SES
ID FETCH-LOGICAL-p141t-522006862c74c2bc4e3632cf06c8b977ef973b9789021d3b77fcf87e4e57046a2
ISSN 0013-7006
IngestDate Sat Sep 28 07:58:45 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Antidepressant
Depression
Efficacy
Psychopharmacologie
Tolérance
Major depressive disorder
Épisode dépressif caractérisé
Dépression
Vortioxétine
Antidépresseur
Efficacité
Psychopharmacology
Thérapeutique
Therapeutics
Trouble dépressif caractérisé
Major depressive episode
Safety
Vortioxetine
Language French
License Copyright © 2015 L’Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p141t-522006862c74c2bc4e3632cf06c8b977ef973b9789021d3b77fcf87e4e57046a2
PMID 26358483
ParticipantIDs pubmed_primary_26358483
PublicationCentury 2000
PublicationDate 2016-Feb
PublicationDateYYYYMMDD 2016-02-01
PublicationDate_xml – month: 02
  year: 2016
  text: 2016-Feb
PublicationDecade 2010
PublicationPlace France
PublicationPlace_xml – name: France
PublicationTitle Encéphale
PublicationTitleAlternate Encephale
PublicationYear 2016
SSID ssj0021490
Score 2.0981383
SecondaryResourceType review_article
Snippet Vortioxetine is a new antidepressant, which mechanism of action is multimodal, targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin...
SourceID pubmed
SourceType Index Database
StartPage 48
SubjectTerms Antidepressive Agents, Second-Generation - pharmacology
Antidepressive Agents, Second-Generation - therapeutic use
Depressive Disorder, Major - drug therapy
Depressive Disorder, Major - psychology
Humans
Piperazines - pharmacology
Piperazines - therapeutic use
Psychiatric Status Rating Scales
Recurrence
Serotonin Agents - pharmacology
Serotonin Agents - therapeutic use
Sulfides - pharmacology
Sulfides - therapeutic use
Title Vortioxetine: a new antidepressant to treat depressive episodes
URI https://www.ncbi.nlm.nih.gov/pubmed/26358483
Volume 42
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NS8MwFA9OL15E8fuLHLyNjqZNk9aLyJgMwZ022W00aYITXcucIv71viTtPlXUSwh5EJr3a1_fe3kfCF1IXxFNI-pFcaqMgUK8NDJWSpxq-MNISn2T4HzXYe0eve1H_VlHQZtdMhEN-fFlXsl_UIU1wNVkyf4B2emmsABzwBdGQBjGX2F8D7rzMH83WcvKZS2DklwHXg3LAFeYWuXS-gGqoNc3VVfF8CXPyvDByi8PB7O35sVD-jSF2zoWFgILm_l4_CrcYmveaUCmccYzQUhCj_s-mxeENFgB3Ek1VwtzRdg6u_-xYUSQKf1JIlsH1XWxnWN_8Wz5b8rexNS1rfmZulQBuyLVUI3Hpj1Hx3hkSqMaLDy_6lJhDlRVlrIxfCtPZmo_l7st2RFWn-huo63SEMDXDtUdtKbHu-hqHtFLnGLAEy_iiSc5tnjiGZ64wnMP9W5a3WbbK1tceAWhZOKB9uuSdCSnMhCSqpCFgdQ-k7EA1VzphIcwMbfBJAsF51rqmCuqIu5Tlgb7aH2Uj9QhwinTGcmSEEhgcmstEsFkxpgKRMaTRByhA3feQeHqmAwqThx_SzlBm7O35xRtaPhw1BloYRNxbmH4BI17LYs
link.rule.ids 780
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vortioxetine%3A+a+new+antidepressant+to+treat+depressive+episodes&rft.jtitle=Enc%C3%A9phale&rft.au=Colle%2C+R&rft.au=Corruble%2C+E&rft.date=2016-02-01&rft.issn=0013-7006&rft.volume=42&rft.issue=1&rft.spage=48&rft_id=info:doi/10.1016%2Fj.encep.2015.07.007&rft_id=info%3Apmid%2F26358483&rft_id=info%3Apmid%2F26358483&rft.externalDocID=26358483
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0013-7006&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0013-7006&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0013-7006&client=summon